

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Stem Cells

Manuscript NO: 66061

Title: Current understanding of mesenchymal stem cell in liver disease

Reviewer's code: 04737606 Position: Editorial Board

Academic degree: DSc, MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Ukraine

Author's Country/Territory: China

Manuscript submission date: 2021-03-20

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-03-21 20:23

Reviewer performed review: 2021-03-22 16:44

Review time: 20 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Current minireview is dedicated to cutting-edge method of the treatment in hepatology and covers both experimental and clinical data. The authors have accurately and widely discussed novel data regarding mentioned topic. Still there are some minor remarks: - firstly, the terms used in the article are in general appropriately abbreviated, but some of the are not, for example NF-kB etc. Thus there is a recommendation for the authors to revise once again all terms and abbreviations used in the article; - secondly, it would be important to mention what possible contraindications are there for the mesenchymal stem cells transplantation - thirdly, are there any data regarding the stage of liver fibrosis that could still be curable with this type of treatment and when mesenchymal stem cells transplantation would not have an effect? Regarding this there is recommendation to mention Child-Pugh and/or MELD score of the patients involved in the trials discussed in the review